RAPT Therapeutics — Technical Presentation (November 2020)
29 slides from RAPT Therapeutics's technical presentation, Nov 16, 2020
Slide 1: FLX475 Clinical Data Update
Transforming the Treatment of Cancer and Inflammation FLX475 Clinical Data Update November 16, 2020 Exhibit 99.3
Slide 2: Legal Disclaimers
Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.’s (the "Company," "we," or "us") research and clinical development pl
Slide 3: FLX475: Oral CCR4 Antagonist for Oncology
FLX475: Oral CCR4 Antagonist for Oncology
Slide 4: Key Takeaways
Key Takeaways Monotherapy responses demonstrate FLX475 is an active agent Combination responses in multiple tumor indications beyond expected from checkpoint inhibition alone Favorable safety profile with broad combinability Biomarker data supports Treg mechanism Multiple cohorts are being expanded
Slide 5: FLX475-02 Phase 1/2 Trial Update: Key Findings
FLX475-02 Phase 1/2 Trial Update: Key Findings Tumor Type Observations Decision EBV+ Hodgkin/Non-Hodgkin Lymphoma Deep and durable response to FLX475 monotherapy Expand monotherapy cohort Expand a combination cohort Nasopharyngeal Carcinoma (NPC) Frequent and deep responses in CPI-naïve patients in
Slide 6: Treg Are Key Targets in the Tumor Microenvironment
Treg Are Key Targets in the Tumor Microenvironment (TME) Correlate with poor prognosis across most cancers Mechanism for immune evasion by viruses and tumors Barrier to checkpoint inhibitor efficacy Challenge: selective inhibition of Treg in the TME Depleting antibodies targeting CD25, CCR4, etc. do
Slide 7: FLX475: CCR4 Antagonist Selectively Targets Tumor Treg
FLX475: CCR4 Antagonist Selectively Targets Tumor Treg Highly potent and selective orally-administered CCR4 small molecule antagonist Selectively blocks tumor Treg while sparing normal tissues and beneficial cells Potential for superior safety and efficacy compared to depleting antibodies Issued US
Slide 8: Identification and Characterization of "Charged" Tumors
Identification and Characterization of “Charged” Tumors “Charged” tumors: high levels of CCR4 ligands, Treg and CD8 T cells Potential for both monotherapy and combination activity Represent cancers with high unmet need and large markets Potential for tissue-agnostic accelerated approval in virally-
Slide 9: FLX475-02: Phase 1 Design, Status and Key Findings
FLX475-02: Phase 1 Design, Status and Key Findings N=6 N=7 N=3 N=3 N=11 N=4 N=3 100 mg 100 mg 75 mg 50 mg 25 mg 75 mg 50 mg FLX475 Monotherapy N=19 FLX475 w/ Pembrolizumab N=18 Standard 3+3 dose escalation in non-charged and charged cancers 37 patients enrolled, 4 remain on study (12-18 months) Favo
Slide 10: PK and PD Support RP2D of 100 mg
PK and PD Phase 1 Data Support RP2D of 100 mg Exposures were dose proportional, and comparable between monotherapy and combo cohorts Doses of 75 mg and above achieved/exceeded the minimum target concentration, with nearly all patients at 100 mg achieving/exceeding minimum target concentration by day
Slide 11: Increases in the CD8:Treg Ratio Observed in Paired Tumor Biopsies
Increases in the CD8:Treg Ratio Observed in Paired Tumor Biopsies from 9 of 11 Patients Treated with FLX475 Density of CD8 and FOXP3 determined by IHC of core tumor biopsies taken prior to treatment and after 2 cycles of treatment Only biopsies recovered from same anatomical site are compared Ratio
Slide 12: Phase 1 Monotherapy (Best Response on Study)
Ph 1 Monotherapy (Best Response on Study) 17 evaluable patients (of 19 enrolled) 1 uPR, 13 SD, 3 PD HPV+ cervical cancer failed prior chemotherapy + bevacizumab Unconfirmed PR after 3 cycles (9 weeks), on study for ~ 6 months NSCLC (adeno), previously treated with chemotherapy + pembrolizumab and pe
Slide 13: Phase 1 Combination Therapy (Best Response on Study)
Ph 1 Combination Therapy (Best Response on Study) 14 evaluable patients (of 18 enrolled) 2 PR, 11 SD, 1 PD Atezolizumab-refractory NSCLC, continues with durable confirmed PR for 18 months Bladder cancer with confirmed PR, on study >9 months HPV+ HNSCC, prior chemo/XRT and progressed after 3 months o
Slide 14: FLX475-02 Phase 2: Gated Simon 2-Stage Design
FLX475-02 Phase 2: Gated Simon 2-Stage Design FLX475 Monotherapy FLX475 w/ Pembrolizumab Nasopharyngeal (EBV+) Non-Small Cell Lung (CPI Experienced) Hodgkin/Non-Hodgkin Lymphoma (EBV+) Head & Neck (CPI Naïve) Cervical (HPV+) (CPI Naïve) TN Breast (CPI Naïve) Head & Neck (CPI Naïve) Head & Neck (CPI
Slide 15: Phase 2 Stage 1 Goals
Phase 2 Stage 1 Goals Initial evaluation of clinical activity in selected charged tumor types Demonstrate preliminary clinical activity of FLX475 as monotherapy Demonstrate preliminary clinical activity of FLX475 in combination with pembrolizumab in checkpoint-naïve cancers Demonstrate preliminary c
Slide 16: EBV+ Lymphoma: Monotherapy Activity Observed
EBV+ Lymphoma: Monotherapy Activity Observed Change in Sum of Product of Diameters (%) CR† †Complete Metabolic Response Mixed Response ^Remains on study First 2 of 2 EBV+ lymphoma patients enrolled experienced significant reduction in size of target lesions, including one with durable complete metab
Slide 17: EBV+ NHL Case: Complete Metabolic Response to FLX475 Monotherapy
EBV+ NHL Case: Complete Metabolic Response to FLX475 Monotherapy EBV+ NK/T NHL 53 y/o, 2L with prior chemotherapy 1H 2019 2 primary lesions L posterior auricular (target), R distal anterior thigh (non target) Deep Durable Response 8-week scan with complete metabolic response (Deauville score of 5 re
Slide 18: NPC Monotherapy Cohort (Best Response on Study)
NPC Monotherapy Cohort (Best Response on Study) 12 patients enrolled, 10 evaluable 7 SD, 3 PD 1 continues on monotherapy^ Level of activity observed does not support Stage 2 enrollment for FLX475 monotherapy However, 7 have crossed over to combination therapy 6 evaluable ^ C Change From Baseline (%)
Slide 19: NPC Crossover: 5/5 CPI-naïve Patients with Tumor Shrinkage
NPC Crossover: 5/5 CPI-naïve Patients with Tumor Shrinkage, 3/5 with Unconfirmed or Deep PR 19 6 evaluable crossover patients, 5 CPI-naïve 5/5 tumor shrinkage, including 1 uPR and 2 deep PRs Published ORR of pembrolizumab alone in CPI-naïve NPC is 26% (all PRs)1 Data support further exploration of c
Slide 20: NPC Patient Response Example
NPC Patient Response Example 58 y/o, prior cisplatin/5FU and palliative XRT; cisplatin/docetaxel in 2019 Started FLX475 monotherapy in January 2020; crossover in April 2020 Partial response first observed at 9 weeks confirmed after 15 weeks with complete resolution of target lesion after 21 weeks Cr
Slide 21: CPI-naïve HNSCC Monotherapy Cohort (Best Response on Study)
Ph 2 CPI-naïve HNSCC Monotherapy Cohort (Best Response on Study) 13 patients enrolled, 10 evaluable 5 SD, 5 PD Level of activity observed does not support Stage 2 enrollment for FLX475 monotherapy However, 6 have crossed over to combination therapy Combination cohort for CPI-naïve HNSCC is being enr
Slide 22: HNSCC CPI-Naïve: Promising Combination Activity
HNSCC CPI-Naïve: Promising Combination Activity (Best Response on Study) Crossover 6 enrolled and evaluable 1 PR, 1uPR, 2 SD (1 with target reduction > 20%), 2 PD Combination Cohort 17 enrolled; 10 evaluable 1 CR, 5 SD (3 with target reduction > 20%), 4 PD ORR of pembrolizumab alone in CPI-naïve HNS
Slide 23: Phase 2 Safety
Phase 2 Safety To date, no new significant safety findings vs Phase 1 No evidence of increased severity or frequency of AEs in combination therapy vs either FLX475 or pembrolizumab given alone Asymptomatic and reversible QTc prolongation continues to be the primary FLX475-related finding Serious adv
Slide 24: Phase 2: Stage Decisions
Phase 2: Stage 2 Decisions Nasopharyngeal (EBV+) Monotherapy Nasopharyngeal (EBV+) Monotherapy Nasopharyngeal (EBV+) Combination * Go to Stage 2 Stop *New cohort Stage 1 (N=10) Stage 2 (N=19) EBV+ Lymphoma Monotherapy EBV+ Lymphoma Monotherapy EBV+ Lymphoma Combination * Pending NSCLC Combination (C
Slide 25: Phase 2 Stage 1 Goals Status
Phase 2 Goals Evaluate initial clinical activity in selected charged tumor types ✓ Demonstrate preliminary clinical activity of FLX475 as monotherapy ✓ Demonstrate preliminary clinical activity of FLX475 in combination with pembrolizumab in checkpoint-naïve cancers Demonstrate preliminary clinical a
Slide 26: CCR4 Drives Tumor Progression and Allergic Inflammation
CCR4 Drives Tumor Progression and Allergic Inflammation FLX475: Highly selective tumor Treg inhibitor with demonstrated antitumor activity and excellent combinability CCR4 Treg CCR4 Th2 Eosinophilia Skin and airway thickening High IgE IL-4 IL-5 IL-13 FLX475 Atopic Dermatitis, Asthma CCR4 Ligands CD8
Slide 27: Next Catalysts
Next Catalysts FLX475: next Phase 2 update expected in 2H 2021 including additional data from Stage 1 cohorts as well as Stage 2 expansions RPT193: data release now expected in 1H 2021
Slide 28: Discovery, Clinical: Oral Drugs Targeting Critical Immune Drivers of Disease
DISCOVERY Oral Drugs Targeting Critical Immune Drivers of Disease FLX475 (Oncology): Selectively targets immunosuppressive tumor Treg Proof of concept established in Phase 2 with multiple expansions underway Next comprehensive Phase 2 update 2H 2021 RPT193 (Allergic Disease): Oral agent targets infl
Slide 29: Thank You
Thank You
RAPT Therapeutics — Technical Presentation (November 2020) on 6ix